Actuate Therapeutics (ACTU) Share-based Compensation (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Share-based Compensation of $1.5 million for Q4 2025, up 29.38% year-over-year from $1.2 million in Q4 2024, and down 74.41% quarter-over-quarter from $6.0 million in Q3 2025.
Actuate Therapeutics (ACTU) Share-based Compensation (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Share-based Compensation for 3 consecutive years, with $1.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation rose 29.38% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $5.4 million (up 172.45% YoY), while the FY2025 annual figure was $6.0 million, up 149.45% from the prior year.
- Share-based Compensation retreated to $1.5 million in Q4 2025 per ACTU's latest filing, from $6.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.0 million in Q3 2025 and bottomed at $73131.0 in Q2 2023.
- Historically, Share-based Compensation has averaged $1.1 million across 3 years, with a median of $565981.0 in 2024.
- Annual changes were most pronounced in 2024 — Share-based Compensation climbed 23.09% — and 2025, when it surged 1654.38%.
- Actuate Therapeutics' Share-based Compensation stood at $122050.0 in 2023, then soared by 876.31% to $1.2 million in 2024, then increased by 29.38% to $1.5 million in 2025.
- Business Quant data shows ACTU's Share-based Compensation at $1.5 million in Q4 2025, $6.0 million in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | 1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.54 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 6.02 Mn |
| Sep 30, 2025 | 6.02 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 565,981.00 |
| Sep 30, 2024 | 565,981.00 |
| Jun 30, 2024 | 90,019.00 |
| Jun 30, 2024 | 90,019.00 |
| Mar 31, 2024 | 148,206.00 |
| Mar 31, 2024 | 148,206.00 |
| Dec 31, 2023 | 122,050.00 |
| Dec 31, 2023 | 122,050.00 |
| Sep 30, 2023 | 155,227.00 |
| Sep 30, 2023 | 155,227.00 |